Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**gamma-aminobutyric acid + naproxen** is a combination product consisting of gamma-aminobutyric acid as a component of a proprietary amino-acid medical food formulation and the nonsteroidal anti-inflammatory drug naproxen. In the cited context, this combination corresponds to a convenience-packed pain-management kit in which the medical food component includes gamma-aminobutyric acid alongside other amino acids and nutritional cofactors, while naproxen provides cyclooxygenase inhibition to reduce prostaglandin-mediated pain and inflammation. The product was associated with Physician Therapeutics and its parent company Targeted Medical Pharma, and appears to have been positioned for pain management rather than as a single new molecular entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gamma-aminobutyric acid + naproxen.